Phase 2 Pancreatic Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 75 years, of any gender
• People who have been confirmed by laboratory testing (tissue or cell sample) to have pancreatic cancer that started in the ductal lining of the pancreas, and whose cancer has been assessed by a specialist team as either removable by surgery or "borderline removable" with certain high-risk features — specifically, a blood marker called CA19-9 above 200 U/mL, a tumour larger than 2 cm, or cancer that has spread to nearby lymph nodes (confirm with trial site for full definition)
• People who have at least one tumour that can be measured on scans, according to standard measurement guidelines
• People who have not previously received any anti-cancer treatment, including radiotherapy, chemotherapy, targeted therapy, immunotherapy, ablation, or any experimental drug treatment
• People with a general health and activity level rated 0 or 1 on a standard medical scale (meaning fully active or restricted only in physically demanding activity)
• People with a life expectancy of at least 3 months
• People whose blood counts, liver function, kidney function, clotting, and heart function all meet specific minimum standards on recent tests — details include adequate levels of blood cells, proteins, liver enzymes, kidney markers, and heart function on ECG and heart ultrasound (confirm with trial site for exact values)
• Women who could become pregnant must have a negative pregnancy blood test within 3 days before joining, and must agree to use appropriate contraception during the study and for 6 months after treatment ends
• Men must either be surgically sterile or agree to use appropriate contraception during the study and for 3 months after treatment ends
• People who voluntarily agree to take part and sign a written consent form

Who may not be able to join:

• People whose pancreatic cancer originated from a different type of pancreatic cell — for example, neuroendocrine tumours, acinar cell carcinoma, pancreatoblastoma, or solid-pseudopapillary neoplasms
• People with known cancer that has spread to the brain or central nervous system
• People with serious digestive system problems such as significant bleeding, bowel obstruction, or severe inflammation or diarrhoea
• People with abnormal fluid build-up in body cavities (other than certain minor ascites) that has not been stable for at least 2 weeks before joining
• People with ascites (fluid in the abdomen) that is causing symptoms and requires draining, or who have had ascites drained in the past 3 months — unless imaging shows only a very small amount that is not causing symptoms
• People with a known lung condition involving scarring or inflammation of lung tissue (interstitial lung disease), beyond minor changes seen only on imaging
• People with known nerve damage in the hands or feet rated as severe (Grade 3 or higher on a standard medical scale)
• People with known deficiency or low activity of an enzyme called dihydropyrimidine dehydrogenase
• People who have had a serious infection in the 4 weeks before joining, such as severe pneumonia requiring hospitalisation or a bloodstream infection, or who have had an infection requiring intravenous antibiotics in the 2 weeks before joining
• People who have recently used certain medications that strongly affect how the body processes drugs (specific enzyme inhibitors or inducers — confirm with trial site), or who have had radiotherapy in the 2 weeks before joining, major surgery in the 4 weeks before joining, or another experimental treatment in the 4 weeks before joining
• People with abnormal blood clotting, a tendency to bleed, or who are currently receiving clot-dissolving or blood-thinning therapy — low-dose aspirin and low-dose preventive blood thinners such as low molecular weight heparin are permitted
• People with uncontrolled heart problems, including moderate-to-severe heart failure, unstable chest pain (angina), a heart attack in the past 6 months, or significant irregular heart rhythms requiring treatment
• People who have had another type of cancer in the past 5 years, with exceptions for certain treated skin cancers or cervical carcinoma in situ
• People with a known allergy or hypersensitivity to any of the study drugs or their ingredients (including irinotecan liposome, oxaliplatin, 5-FU, leucovorin calcium, or adadelimab)
• People known to have HIV/AIDS or an active syphilis infection
• People with a confirmed significant neurological or psychiatric condition, including epilepsy or dementia
• People who, in the judgement of the trial investigator, have other circumstances that could affect their safety or ability to complete the trial (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.